Participants in this study have an advanced form of prostate cancer that has gotten worse after other treatment and suffer from pain due to the spread of prostate cancer to the bones. Participants will receive the investigational drug cabozantinib (XL184) or mitoxantrone plus prednisone, a drug combination used in treating patients with their type of cancer. Cabozantinib is considered an investigational drug for use in prostate cancer because it has not been approved by any regulatory authorities (US Food and Drug Administration [FDA] or European Medicines Agency [EMA]). Mitoxantrone and prednisone are approved by the FDA and other health authorities worldwide and are commercially available. The primary purpose of this study is to find out if cabozantinib is effective in reducing cancer pain compared with mitoxantrone plus prednisone. Up to 246 people at approximately 50 centers in North America, the United Kingdom, and Australia will take part in this study.
Pamela Zehr, 319-353-8914
The purpose of this study is to determine whether the mechanisms (biological reasons) of how a single meal high in saturated fat or trans- fat causes a temporary impairment of blood vessel function in younger and older adults and how regular physical activity (exercise) may prevent this from occurring. If this does occur, we may better understand the mechanisms of vascular dysfunction and how to prevent this in patients in the future.
We are inviting you to participate in this research study because you are a non-smoking healthy male or female not on medications for high cholesterol and are between age of 18 -35 or 50-79 years and are sedentary, often not physically active (50-79 group) or highly physically active (50-79 group only). Women over 50 years of age will be postmenopausal for at least the past 1 year.
If you agree to take part in this study, your involvement will last for approximately 4-5 weeks and involve 5 separate visits. Visits will range from 1 to 5 hours. Visit 1 will last approximately 1 hour and Visit 2 will last approximately 2 hours. These are your screening visits and will determine your eligibility to participate in the study. If you are eligible to continue, Visits 3, 4 and 5 will occur over a 3 week period and each will last approximately 5 hours.
Kaitlyn Dubishar Phone: (319) 353-3037
The purpose of this study is to test the safety of the research study drug, dinaciclib (MK-7965) and to compare the effectiveness of dinaciclib and ofatumumab in treating patients with Chronic Lymphocytic Leukemia (CLL). This is a research study to test a drug that has not yet been approved for sale. Ofatumumab may be available by prescription for the treatment of CLL. The use of ofatumumab for 12 months has not yet been approved.
Karen Parrott, 319-353-6347
A research study looking at genes involved in head, face and eye disorders is enrolling individuals and families with disorders that affect the head, face, and/or eye, such as cleft lip and palate or dental anomalies. The study involves providing a saliva sample along with medical and health information. Individuals interested in the study should contact Nichole Nidey (firstname.lastname@example.org) at the Craniofacial Genetics Research Center.
(319)353-4365 or 866-520-8982 Ext.2
(319) 353-4365 or 866-520-8982 Ext.2
If you have a close relative with type 1 diabetes, your risk of developing the disease increases from one in 250 to one in 20. A simple blood test can reveal the risk for type 1 diabetes up to 10 years before diagnosis. Those found to be at increased risk may then be eligible to join studies that test ways to dely or prevent diagnosis of type 1 diabetes.
Please help us improve your experience on our website by completing a brief survey
Yes, I'll give feedback No, Thanks
Your browser does not support iframes.